COVID-19 Update: Economic Impact, Biopharma Response, and Consequences
Managing Director and regular PharmaBoardroom contributor David H. Crean. Ph.D looks at how the ongoing global coronavirus (COVID-19) outbreak has impacted the global economy, how the biopharmaceutical industry is responding, and what the longer-term consequences of the crisis and responses to it will be. This article was originally published on PharmaBoardroom.com on March 3, […]
Is Your Business Prepared For An Economic Downturn?
Managing Director, David H. Crean, Ph.D, serves as a Forbes Council Member providing M&A thought leadership and insights for business owners. This article was originally published on Forbes.com on January 27, 2020 at 8:00AM PST. Small businesses are often hit the hardest during an economic downturn. Staff cutbacks, sluggish demand and reduced cash […]
Objective Capital Partners Strengthens Its Execution Capability with New Managing Director Carl Miller
San Diego, CA – January 31, 2020 – Objective Capital Partners, a leading M&A investment banking firm providing M&A, Corporate Development, and Valuation Advisory Services, is pleased to announce that Carl Miller has joined the firm as a Managing Director. Carl is an exceptional investment banking professional who will enhance the execution capabilities of […]
Trever F. Acers Named San Diego Top 500 Most Influential Business Leader for Fifth Consecutive Year
San Diego, CA – January 7, 2019 – Objective Capital Partners, a leading M&A investment banking firm providing M&A, Corporate Development, and Valuation Advisory Services, is pleased to announce that Managing Director Trever F. Acers has been named a San Diego Top 500 Most Influential Business Leader by the San Diego Business Journal for […]
How To Determine Your Company’s Worth And Increase Its Value
Managing Director, David H. Crean, Ph.D, serves as a Forbes Council Member providing M&A thought leadership and insights for business owners. This article was originally published on Forbes.com on November 14, 2019 at 8:00AM PST. When it comes time to sell a business, business owners should know their minimum target sales price in […]
Objective Capital Partners Advises Sale of Toft Group to ZRG Partners
San Diego, CA, Dec. 05, 2019 — Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive financial advisor to Toft Group in their sale to ZRG Partners, one of the fastest growing global executive search firms and a portfolio company of RFE Investment […]
How to Walk Away From Every Networking Event With New Connections
Suit up, show up, meet, greet, shake hands, pitch yourself / your business, and ask questions. Repeat until you’ve made connections with people who could potentially help you or you wish to meet. Just thinking about the concept of networking makes many people experience agita. The problem is that networking is a major part […]
Fertility Industry Report: 2019 Review
Globally, fertility clinics generated revenue of approximately $9 billion in 2017. The United States accounted for $3.6 billion of this market in the same year and the industry is expected to grow by almost a billion dollars by 2022. Consolidation in the fertility space has been occurring at a rapid pace for the past several […]
Genomics Industry Report: 2019 Review
Since the first human genome was sequenced in 2003, at a cost of $3 billion, Genomics companies have been innovating to provide less expensive, faster, and higher quality solutions. This high-growth industry is currently valued at an estimated $15.5 billion, with further growth predicted to tip 8.6% over the next five years. Consolidation in the […]
Contract Research Organization Industry Report: 2019 Review
Contract Research Organizations (CROs) have evolved over the last several decades into fully outsourced providers of drug development products and services from pre-clinical and discovery services, to clinical (often referred to as Phase I-III), to Phase IV/post-approval monitoring and commercialization. The industry itself is estimated to be $30 billion and it is highly fragmented […]